Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Durata Plans To Pitch Dalbavancin As Cost-Saving Paradigm Changer

Executive Summary

Company plans to file an NDA for the antibiotic in September, built partly on clinical work done by the drug’s previous owner, Pfizer. Given hospitals’ emphasis on cost, Durata’s marketing plan will highlight the drug’s two-dose regimen, which could help move treatment to the ambulatory-care setting.

You may also be interested in...

Orbactiv Launch Strategy Will Focus On Savings From Avoiding Hospitalization

The novel antibiotic will fit well into a treatment paradigm moving more toward outpatient care, The Medicines Co. execs explained to investors. The firm will stress cost savings, reduced need for hospitalization and a virtual guarantee of patient compliance.

The Medicines Co. Joins Crowded Antibiotic Field With Q4 Orbactiv Launch

Company is banking on its single-dose treatment course to propel it over competitors in a crowded generic and branded space, but this may involve major changes in treatment practice, analysts say.

Cubist’s Sivextro To Beat Durata’s Dalvance To Antibiotic Market

Second QIDP antibiotic is first to market; Cubist will stress shorter term dosing over available therapies and thinks it can rely on efficient marketing strategy for commercial success.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts